x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243067
| Product Information | |
|---|---|
| CAS No. | 1423018-12-5 |
| Formula | C28H29NO4S |
| Molecular Weight | 475.60 |
| SMILES | COC1=C(N(CC2=CC=C(COC3=CC=C([C@@H](C#CC)CC(O)=O)C=C3)S2)CCC4)C4=CC=C1 |
| Target | Free Fatty Acid Receptor |
| Product Description | LY2922470 is a potent, selective and orally available agonist of the G protein-coupled receptor 40 (GPR40), with EC50s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. LY2922470 reduces glucose levels along with significant increases in insulin and GLP-1, is potential for the treatment of type 2 diabetes mellitus (T2DM). |
| Format & Storage | |
|---|---|
| Format | Solid |
| Color | Off-white to light yellow |
| Purity | 99.87% |
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | In solvent: -80°C, 6 months; -20°C, 1 month (protect from light) |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
